GURU.Markets stock price, segment price, and overall market index valuation
The company's share price Assertio Holdings Inc.
Assertio is a pharmaceutical company specializing in drugs for the treatment of neurological diseases. Its stock price reflects its complex history, including restructuring and reliance on sales of a small portfolio of established drugs.
Share prices of companies in the market segment - Neuro
Assertio Holdings is a pharmaceutical company that commercializes drugs for the treatment of neurological, orthopedic, and pain conditions. We classify it as part of the Neurology sector. The chart below shows how this segment of the pharmaceutical market is performing.
Broad Market Index - GURU.Markets
Assertio Holdings is a pharmaceutical company specializing in the commercialization of drugs for the treatment of central nervous system diseases. As a major player, it is included in our GURU.Markets index. The chart below shows the overall market trend. Compare it with Assertio's performance to assess the state of the sector.
Change in the price of a company, segment, and market as a whole per day
ASRT - Daily change in the company's share price Assertio Holdings Inc.
Assertio Holdings, Inc.'s daily price change reflects the volatility inherent in pharmaceutical companies with mature product portfolios. The metric demonstrates sensitivity to generic competition and the success of commercial strategies.
Daily change in the price of a set of shares in a market segment - Neuro
Assertio Holdings, Inc.'s daily price change reflects the volatility inherent in pharmaceutical companies with mature product portfolios. The metric demonstrates sensitivity to generic competition and the success of commercial strategies.
Daily change in the price of a broad market stock, index - GURU.Markets
Assertio is a pharmaceutical company specializing in drugs for the treatment of neurological diseases. Its stock price is driven by sales volume, competition, and the patent cycle. These industry-specific factors create fluctuations that contribute to the overall volatility of the healthcare sector and the market as a whole.
Dynamics of market capitalization of the company, segment and the market as a whole over 12 months
Annual dynamics of the company's market capitalization Assertio Holdings Inc.
Assertio Holdings, Inc.'s year-over-year performance tells the story of its portfolio of mature pharmaceutical brands. Its market capitalization over the past 12 months reflects its ability to maximize revenue from these drugs while managing their life cycles, and its acquisition strategy to sustain growth in a competitive environment.
Annual dynamics of market capitalization of the market segment - Neuro
Assertio Holdings, Inc. is a pharmaceutical company specializing in the commercialization of niche drugs. Its growth strategy is based on acquisitions. The chart shows how its M&A activity and ability to successfully integrate and market new products impact its growth.
Annual dynamics of market capitalization of broad market stocks, index - GURU.Markets
Assertio, which specializes in drugs for neurological diseases, operates in a complex niche. Its stock price is driven not by the economy, but by sales volume, generic competition, and its ability to expand its portfolio. This chart tells the story of how the company is struggling to grow in the highly competitive pharmaceutical market.
Dynamics of market capitalization of the company, segment and the market as a whole for the month
Monthly dynamics of the company's market capitalization Assertio Holdings Inc.
Assertio Holdings is a pharmaceutical company specializing in neuroscience and pain management products. Its monthly performance reflects sales of its product portfolio and success in managing their lifecycles. Quarterly revenue and profitability reports are key to its valuation.
Monthly dynamics of market capitalization of the market segment - Neuro
Assertio Holdings, Inc. is a pharmaceutical company specializing in the commercialization of branded drugs for the treatment of neurological and rheumatological diseases. The dynamics of its sector, shown in the chart, serve as background. It is interesting to assess how its strategy of acquiring and promoting existing drugs impacts its profitability.
Monthly dynamics of market capitalization of broad market stocks, index - GURU.Markets
Assertio is a pharmaceutical company focused on commercializing approved drugs. Its stock price is driven by sales reports and competitive news. The chart shows how the company's performance is influenced by its commercial success, making it more predictable than research-stage biotechs.
Dynamics of market capitalization of the company, segment and the market as a whole for the week
Weekly dynamics of the company's market capitalization Assertio Holdings Inc.
Assertio Holdings, a pharmaceutical company specializing in drugs for neurological diseases, whose weekly stock performance reflects the success of its portfolio commercialization. Sales data and market competition drive short-term fluctuations.
Weekly dynamics of market capitalization of the market segment - Neuro
Assertio Holdings commercializes pharmaceuticals, primarily in neuroscience. Its success depends on marketing and patent protection. The chart compares its weekly performance with the pharmaceutical sector to understand what influences it more: sales performance or general industry trends.
Weekly dynamics of market capitalization of stocks of the broad market, index - GURU.Markets
Assertio Holdings commercializes pharmaceuticals. Its business depends on successful sales and patent protection. The chart will help you assess whether ASRT shares move with the market or are driven by unique factors such as sales reports and competition.
Market capitalization of the company, segment and market as a whole
ASRT - Market capitalization of the company Assertio Holdings Inc.
Assertio Holdings's chart is a financial history of the pharmaceutical business's transformation. Its market capitalization reflects the company's strategy of acquiring and commercializing already approved drugs. Its dynamics are a barometer of how successfully the company can manage its portfolio and generate cash flow in a competitive environment.
ASRT - Share of the company's market capitalization Assertio Holdings Inc. within the market segment - Neuro
Assertio's market share in the neurosciences sector reflects its strategy of commercializing existing, proven drugs. Its market share stems not from revolutionary discoveries, but from effective marketing and product lifecycle management to meet patient needs.
Market capitalization of the market segment - Neuro
Assertio Holdings is a pharmaceutical company specializing in neuroscience and pain medications. The chart below shows the overall market capitalization of the entire industry. Its dynamics provide the backdrop against which Assertio is attempting to commercialize its niche products.
Market capitalization of all companies included in a broad market index - GURU.Markets
Assertio is a pharmaceutical company that specializes in commercializing drugs for the treatment of neurological diseases. Its market capitalization reflects its focus on this market. The chart below shows the economic weight of companies focused on neurology.
Book value capitalization of the company, segment and market as a whole
ASRT - Book value capitalization of the company Assertio Holdings Inc.
For Assertio Holdings, a pharmaceutical company, book value is its equity and rights to its drugs. The chart below shows how the company manages its product portfolio. Its dynamics can reflect both the acquisition of new drugs and the write-off of old ones.
ASRT - Share of the company's book capitalization Assertio Holdings Inc. within the market segment - Neuro
Assertio Holdings is a pharmaceutical company specializing in neuroscience and pain management drugs. It acquires and commercializes already approved products. Its physical assets are distribution infrastructure, not R&D, which will be reflected in the chart.
Market segment balance sheet capitalization - Neuro
Assertio Holdings is a pharmaceutical company that uses a "light" model. It acquires rights to already approved drugs and commercializes them without owning manufacturing facilities. The graph will show whether this business model is the norm for the entire pharmaceutical industry, or whether competitors prefer vertical integration.
Book value of all companies included in the broad market index - GURU.Markets
Assertio Holdings' assets comprise a portfolio of commercialization rights for already approved pharmaceuticals in neurology and pain management. Its book value reflects its business model: acquisition and marketing of existing drugs rather than development, which requires lower R&D costs.
The ratio of market capitalization to book capitalization of a company, segment, and the market as a whole
Market capitalization to book capitalization ratio - Assertio Holdings Inc.
Assertio is a pharmaceutical company that acquires and commercializes already approved drugs. Its value lies not in its R&D, but in its ability to effectively market these products. Its market capitalization reflects the cash flows from its drug portfolio. The chart shows how the market perceives the stability of these flows and the risk of losing exclusivity.
Market to book capitalization ratio in a market segment - Neuro
Assertio Holdings is a pharmaceutical company specializing in neuroscience drugs. Its business model is based on the acquisition and commercialization of already approved products. The chart shows how the market values its current drug portfolio and cash flow generation capacity.
Market to book capitalization ratio for the market as a whole
Assertio Holdings is a pharmaceutical company specializing in the commercialization of drugs for the treatment of neurological diseases. The chart shows how the market values its product portfolio. The company's value is determined by the sales volume of its drugs and its ability to effectively market them, which determines its market valuation relative to its tangible assets.
Debts of the company, segment and market as a whole
ASRT - Company debts Assertio Holdings Inc.
Assertio Holdings is a pharmaceutical company specializing in the commercialization of products for the treatment of neurological diseases. Its strategy often involves acquiring rights to existing drugs. Debt is a tool for financing such deals, as this chart illustrates.
Market segment debts - Neuro
Assertio Holdings is a pharmaceutical company specializing in the commercialization of drugs for the treatment of neurological diseases and pain. Their business model is focused on marketing and selling approved drugs. This chart shows common financial metrics for the pharmaceutical sector, allowing one to evaluate how Assertio manages its capital to maximize sales of its portfolio.
Market debt in general
Debt to book value of the company, segment and market as a whole
The company's debt to book capitalization ratio Assertio Holdings Inc.
Assertio Holdings is a pharmaceutical company focused on commercializing drugs for neurological diseases. Its strategy often involves acquiring rights to existing drugs. This chart shows how actively the company uses debt to finance such deals, allowing us to assess the risks of its business model.
Market segment debt to market segment book capitalization - Neuro
Assertio's business model, selling branded pharmaceuticals, differs from developing new drugs. This chart shows the debt burden in the pharmaceutical industry. It allows us to appreciate how Assertio's financial strategy, focused on commercializing existing products, differs from that of R&D companies with their enormous research expenditures.
Debt to book value of all companies in the market
Assertio Holdings commercializes pharmaceuticals, often acquiring the rights to existing drugs. This model can require significant leverage for transactions. This chart shows how their acquisition-based growth strategy impacts their leverage relative to the market as a whole.
P/E of the company, segment and market as a whole
P/E - Assertio Holdings Inc.
This chart shows the valuation of Assertio Holdings, Inc., a pharmaceutical company specializing in drugs for neurological diseases. The metric reflects how investors view its portfolio of commercialized products and its acquisition strategy to support future growth.
P/E of the market segment - Neuro
This chart shows the average valuation for the specialty pharmaceutical sector in which Assertio Holdings operates. This metric reflects how investors generally value companies managing a portfolio of mature drugs. It helps understand how the market views Assertio's business model compared to other pharmaceutical companies.
P/E of the market as a whole
Assertio Holdings is a pharmaceutical company that acquires and commercializes existing branded drugs. Its strategy is not development, but rather the effective management and marketing of mature products. This chart shows the sentiment in the pharmaceutical sector. It helps understand how the market views this business model, which carries fewer R&D risks but relies on the ability to extend the life of legacy brands.
Future P/E of the company, segment and market as a whole
Future (projected) P/E of the company Assertio Holdings Inc.
Assertio Holdings is a pharmaceutical company specializing in the commercialization of drugs for the treatment of nervous system disorders and pain management. Its future revenue depends on sales of its existing product portfolio and its successful lifecycle management. This chart shows how the market views its commercial strategy and ability to generate cash flow from its generic and branded drugs.
%20P%2FE%20Assertio%20Holdings%20Inc.&width=1500&height=450&colorIndex=35&filename=GURU_Markets_-_Chart-of-the-companys-future-projected-PE-Assertio-Holdings-Inc.&v=1772636771295 "Chart of the company's future (projected) P/E Assertio Holdings Inc.")
Future (projected) P/E of the market segment - Neuro
Assertio Holdings is a pharmaceutical company that acquires and commercializes approved drugs, primarily in neuroscience and pain management. This business model is based on marketing rather than R&D. The chart shows expectations for the pharmaceutical sector, helping to understand how the market views this commercial, rather than scientific, strategy.
%20P%2FE%20graph%20of%20the%20market%20segment%20-%20Neuro&width=1500&height=450&colorIndex=36&filename=GURU_Markets_-_Future-projected-PE-graph-of-the-market-segment-Neuro&v=1772636771302 "Future (projected) P/E graph of the market segment - Neuro")
Future (projected) P/E of the market as a whole
Assertio Holdings is a pharmaceutical company that acquires and commercializes approved drugs, primarily in neurology and pain management. Their business model is less risky than developing them from scratch. This general expectations chart reflects the stability of the healthcare system. Market optimism indicates predictable demand for drugs, which is important for Assertio's business model.
%20P%2FE%20of%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=37&filename=GURU_Markets_-_Chart-of-the-future-projected-PE-of-the-market-as-a-whole&v=1772636771305 "Chart of the future (projected) P/E of the market as a whole")
Profit of the company, segment and market as a whole
Company profit Assertio Holdings Inc.
Assertio Holdings is a pharmaceutical company specializing in the commercialization of drugs for the treatment of neurological diseases. This chart illustrates the results of its sales-driven business model. Profits depend on sales volumes of existing products and the ability to acquire or license new drugs to expand its portfolio.
Profit of companies in the market segment - Neuro
BioAtla, Inc. is a biotechnology company developing antibodies that are activated only in tumors, increasing their safety. This graph reflects the state of innovative oncology, where scientific breakthroughs aimed at improving treatment specificity can lead to the creation of best-in-class drugs and, consequently, high profitability.
Overall market profit
Assertio Holdings is a pharmaceutical company specializing in the commercialization of drugs for the treatment of neurological diseases. Its business model is based on the acquisition and promotion of already approved products. The company's success depends on the effectiveness of its marketing strategy and product lifecycle management.
Future (predicted) profit of the company, segment and market as a whole
Future (projected) profit of the company Assertio Holdings Inc.
Assertio Holdings is a pharmaceutical company specializing in the commercialization of drugs for the treatment of neurological diseases and pain management. Its profit forecast depends on sales of existing products and successful lifecycle management. This chart shows analyst expectations for the stability of the company's product portfolio.
%20profit%20of%20the%20company%20Assertio%20Holdings%20Inc.&width=1500&height=450&colorIndex=41&filename=GURU_Markets_-_Graph-of-future-projected-profit-of-the-company-Assertio-Holdings-Inc.&v=1772636771338 "Graph of future (projected) profit of the company Assertio Holdings Inc.")
Future (predicted) profit of companies in the market segment - Neuro
Assertio Holdings is a pharmaceutical company that commercializes approved drugs, primarily in neurology and pain management. Its business model is marketing and sales, not R&D. This chart shows profitability projections for the pharmaceutical sector. It helps assess how successful Assertio's strategy is in an innovation-driven industry.
%20profits%20of%20companies%20in%20a%20market%20segment%20-%20Neuro&width=1500&height=450&colorIndex=42&filename=GURU_Markets_-_Graph-of-future-predicted-profits-of-companies-in-a-market-segment-Neuro&v=1772636771351 "Graph of future (predicted) profits of companies in a market segment - Neuro")
Future (predicted) profit of the market as a whole
Assertio Holdings commercializes pharmaceuticals, particularly in the field of neurology. The company's sales are dependent on demand for its products and the competitive environment. General economic expectations, reflected in this chart, can impact the ability of patients and insurers to pay, as well as overall healthcare spending in the country.
%20profits%20of%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=43&filename=GURU_Markets_-_Chart-of-future-predicted-profits-of-the-market-as-a-whole&v=1772636771358 "Chart of future (predicted) profits of the market as a whole")
P/S of the company, segment and market as a whole
P/S - Assertio Holdings Inc.
Assertio Holdings is a pharmaceutical company that acquires and commercializes approved drugs, primarily in neurology and pain management. Its business model is marketing rather than development. The chart shows how investors assess its ability to effectively market its pipeline and generate cash flow from mature products.
P/S market segment - Neuro
Assertio Holdings, Inc. is a commercial pharmaceutical company offering specialized medications in neurology, rheumatology, and pain management. Its revenue is generated from sales of existing branded medications. This chart shows the average valuation in the sector, allowing one to assess the market's perception of Assertio's product portfolio.
P/S of the market as a whole
Assertio Holdings is a pharmaceutical company that commercializes existing drugs, primarily in the neuroscience field. Its business model is based on acquiring rights to drugs. This chart shows the average investor-to-revenue ratio, which allows one to assess the value of a company's revenue operating under the "discovery and commercialization" model in the pharmaceutical industry.
Future P/S of the company, segment and market as a whole
Future (projected) P/S of the company Assertio Holdings Inc.
Assertio Holdings is a pharmaceutical company specializing in the commercialization of drugs for the treatment of neurological diseases and other disorders. This chart shows how investors estimate future revenue from sales of its drug portfolio. The dynamics depend on the success of its marketing efforts and market competition.
%20P%2FS%20Assertio%20Holdings%20Inc.&width=1500&height=450&colorIndex=47&filename=GURU_Markets_-_The-graph-of-the-companys-future-projected-PS-Assertio-Holdings-Inc.&v=1772636771399 "The graph of the company's future (projected) P/S Assertio Holdings Inc.")
Future (projected) P/S of the market segment - Neuro
Assertio Holdings is a pharmaceutical company that acquires and commercializes approved drugs, primarily for the treatment of neurological diseases and pain syndromes. Its business model is based on managing mature products. The chart shows how the market values Assertio's future revenue, reflecting its ability to effectively manage its portfolio.
%20P%2FS%20market%20segment%20graph%20-%20Neuro&width=1500&height=450&colorIndex=48&filename=GURU_Markets_-_Future-projected-PS-market-segment-graph-Neuro&v=1772636771404 "Future (projected) P/S market segment graph - Neuro")
Future (projected) P/S of the market as a whole
Future revenue expectations in the pharmaceutical industry depend on companies' ability to effectively commercialize approved drugs. Assertio Holdings specializes in acquiring and marketing niche drugs. Their business model demonstrates that revenue growth can be generated not only through R&D but also through effective marketing and portfolio management.
%20P%2FS%20of%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=49&filename=GURU_Markets_-_Chart-of-the-future-projected-PS-of-the-market-as-a-whole&v=1772636771409 "Chart of the future (projected) P/S of the market as a whole")
Sales of the company, segment and market as a whole
Company sales Assertio Holdings Inc.
Assertio Holdings is a pharmaceutical company that acquires and commercializes approved drugs. Its revenue is generated through sales of a portfolio of drugs, primarily for the treatment of neurological diseases and pain. This chart shows how its strategy for managing mature pharmaceutical brands translates into financial results.
Sales of companies in the market segment - Neuro
Assertio Holdings is a pharmaceutical company that acquires and commercializes approved drugs, primarily in neurology and pain management. This chart shows total revenue in the neurology pharmaceutical segment. It reflects the stable demand for proven drugs, which Assertio builds its business model on, avoiding the risks of early development.
Overall market sales
Assertio Holdings is a pharmaceutical company specializing in the commercialization of drugs for the treatment of neurological and pain conditions. Its business model is based on the sale of existing branded medications. Success depends on effective marketing and competition. This global healthcare situation influences demand and pricing for its products.
Future sales volume of the company, segment and market as a whole
Future (projected) sales of the company Assertio Holdings Inc.
Assertio Holdings is a pharmaceutical company specializing in the commercialization of drugs for the treatment of neurological diseases and pain. Its revenue depends on sales of its existing product portfolio. The chart shows analyst revenue forecasts, which reflect their expectations for demand for the company's drugs and the competitive market environment.
%20sales%20of%20the%20company%20Assertio%20Holdings%20Inc.&width=1500&height=450&colorIndex=53&filename=GURU_Markets_-_Schedule-of-future-projected-sales-of-the-company-Assertio-Holdings-Inc.&v=1772636771491 "Schedule of future (projected) sales of the company Assertio Holdings Inc.")
Future (projected) sales of companies in the market segment - Neuro
Assertio Holdings is a pharmaceutical company specializing in the commercialization of drugs for the treatment of central nervous system diseases and neurological disorders. Its business model is based on the acquisition of already approved products. This chart reflects forecasts for the entire neurological pharmaceutical segment, demonstrating analysts' overall expectations for this market.
%20sales%20of%20companies%20in%20the%20market%20segment%20-%20Neuro&width=1500&height=450&colorIndex=54&filename=GURU_Markets_-_Schedule-of-future-projected-sales-of-companies-in-the-market-segment-Neuro&v=1772636771538 "Schedule of future (projected) sales of companies in the market segment - Neuro")
Future (projected) sales of the market as a whole
Assertio Holdings is a pharmaceutical company specializing in the commercialization of drugs for the treatment of nervous system disorders. Its revenue depends on sales of its existing portfolio and the successful acquisition of new products. This general economic activity pattern influences healthcare costs, which determine the volume of prescriptions for Assertio's drugs.
%20sales%20of%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=55&filename=GURU_Markets_-_Schedule-of-future-predicted-sales-of-the-market-as-a-whole&v=1772636771544 "Schedule of future (predicted) sales of the market as a whole")
Marginality of the company, segment and market as a whole
Company marginality Assertio Holdings Inc.
Assertio Holdings is a pharmaceutical company specializing in the commercialization of drugs for the treatment of neurological diseases. This metric reflects the effectiveness of its business model. It shows what portion of its product revenue the company converts into net profit by managing marketing expenses and its drug portfolio.
Market segment marginality - Neuro
Assertio Holdings is a pharmaceutical company specializing in the commercialization of neuroscience and pain treatment drugs. Profitability depends on the effectiveness of its commercial team and product portfolio management. This metric demonstrates the operating profitability of its business model compared to other specialized pharmaceutical companies.
Market marginality as a whole
Assertio Holdings is a pharmaceutical company specializing in the commercialization of drugs for the treatment of neurological and rheumatological diseases. Their business model is based on the acquisition and promotion of already approved products. This overall profitability curve impacts them through the overall solvency of the healthcare system and patients.
Employees in the company, segment and market as a whole
Number of employees in the company Assertio Holdings Inc.
Assertio Holdings is a pharmaceutical company specializing in drugs for neurological diseases. The size of its sales team is crucial for its business. This chart shows the size of its sales and marketing teams. The dynamics here illustrate how the company adapts its marketing efforts.
Share of the company's employees Assertio Holdings Inc. within the market segment - Neuro
Assertio Holdings is a pharmaceutical company specializing in the commercialization of drugs for the treatment of neurological diseases. This chart shows the percentage of sales and marketing specialists the company employs in this niche. Its team is focused on promoting already approved drugs to the market.
Number of employees in the market segment - Neuro
Assertio Holdings, Inc. is a pharmaceutical company specializing in the commercialization of drugs for the treatment of neurological diseases. This chart shows the overall employment in the neurology sector. It illustrates the company's business model, which does not involve developing new drugs from scratch, but rather acquiring and effectively marketing already approved products.
Number of employees in the market as a whole
Assertio Holdings is a pharmaceutical company that commercializes approved drugs, focusing on neurology and pain management. Its business model is based on effective marketing and sales. This total employment chart also includes companies whose staff consists primarily of sales and distribution specialists who ensure drug accessibility for patients.
Market capitalization per employee (in thousands of dollars) of the company, segment, and market as a whole
Market capitalization per employee (in thousands of dollars) of the company Assertio Holdings Inc. (ASRT)
Assertio Holdings, Inc. is a pharmaceutical company specializing in the commercialization of drugs for the treatment of neurological diseases. This chart helps understand its business model. The moderate capitalization per employee may indicate the company's focus on sales and marketing, which requires a larger staff than purely scientific R&D companies.
%20of%20the%20company%20Assertio%20Holdings%20Inc.%20(ASRT)&width=1500&height=450&colorIndex=63&filename=GURU_Markets_-_Chart-of-market-capitalization-per-employee-in-thousands-of-dollars-of-the-company-Assertio-Holdings-Inc.-ASRT&v=1772636771630 "Chart of market capitalization per employee (in thousands of dollars) of the company Assertio Holdings Inc. (ASRT)")
Market capitalization per employee (in thousands of dollars) in the market segment - Neuro
Assertio Holdings is a pharmaceutical company specializing in the commercialization of drugs for neurology and other fields. Their business model is more focused on marketing and sales than R&D. This metric reflects the effectiveness of their commercial team. A high score indicates the ability to successfully market drugs and generate revenue with a relatively small staff.
%20by%20market%20segment%20-%20Neuro&width=1500&height=450&colorIndex=64&filename=GURU_Markets_-_Market-capitalization-per-employee-in-thousands-of-dollars-by-market-segment-Neuro&v=1772636771720 "Market capitalization per employee (in thousands of dollars) by market segment - Neuro")
Market capitalization per employee (in thousands of dollars) for the overall market
Assertio Holdings, Inc. is a pharmaceutical company specializing in the commercialization of neuroscience drugs. Its business model is focused on marketing and selling approved drugs. The employee's performance appraisal will reflect the effectiveness of its commercial team and the profitability of its acquired or licensed product portfolio.
%20for%20the%20overall%20market&width=1500&height=450&colorIndex=65&filename=GURU_Markets_-_Market-capitalization-per-employee-in-thousands-of-dollars-for-the-overall-market&v=1772636771843 "Market capitalization per employee (in thousands of dollars) for the overall market")
Profit per employee (in thousands of dollars) for the company, segment, and market as a whole
Profit per employee (in thousands of dollars) of the company Assertio Holdings Inc. (ASRT)
Assertio is a pharmaceutical company, but its model is commercialization rather than R&D. They acquire the rights to already approved drugs (primarily in neurology) and handle their marketing. This chart shows how effective their sales team is, measuring the net profit generated by each employee.
%20Chart%20Assertio%20Holdings%20Inc.%20(ASRT)&width=1500&height=450&colorIndex=66&filename=GURU_Markets_-_Company-Profit-Per-Employee-in-thousands-of-dollars-Chart-Assertio-Holdings-Inc.-ASRT&v=1772636771865 "Company Profit Per Employee (in thousands of dollars) Chart Assertio Holdings Inc. (ASRT)")
Profit per employee (in thousands of dollars) in the market segment - Neuro
Assertio Holdings operates on a "buy and commercialize" model for existing pharmaceuticals. This graph is a direct indicator of their effectiveness. Unlike R&D companies, their goal is to maximize sales of acquired products with the help of a small and effective marketing team, exceeding average profitability.
%20in%20the%20market%20segment%20-%20Neuro&width=1500&height=450&colorIndex=67&filename=GURU_Markets_-_Chart-of-profit-per-employee-in-thousands-of-dollars-in-the-market-segment-Neuro&v=1772636771893 "Chart of profit per employee (in thousands of dollars) in the market segment - Neuro")
Profit per employee (in thousands of dollars) for the market as a whole
Assertio (ASRT) is a pharmaceutical company that doesn't develop, but commercializes already approved drugs, often niche ones. Their business is marketing and sales. This metric reflects the efficiency of their sales force. It shows how much revenue their sales team generates by promoting a portfolio of mature or niche drugs.
%20for%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=68&filename=GURU_Markets_-_Chart-of-profit-per-employee-in-thousands-of-dollars-for-the-market-as-a-whole&v=1772636771916 "Chart of profit per employee (in thousands of dollars) for the market as a whole")
Sales to employees of the company, segment and market as a whole
Sales per company employee Assertio Holdings Inc. (ASRT)
This chart for Assertio Holdings, a pharmaceutical company specializing in neuroscience, demonstrates the effectiveness of its commercial strategy. It reflects how successfully a small team markets and sells a portfolio of niche drugs, generating revenue in a highly competitive market.
&width=1500&height=450&colorIndex=69&filename=GURU_Markets_-_Sales-chart-per-company-employee-Assertio-Holdings-Inc.-ASRT&v=1772636771946 "Sales chart per company employee Assertio Holdings Inc. (ASRT)")
Sales per employee in the market segment - Neuro
Assertio Holdings is a pharmaceutical company specializing in the commercialization of neurology and pain management drugs. Their focus is sales. This metric reflects the average revenue per employee in the segment. It allows them to assess how productive their sales force is in promoting existing products compared to other pharmaceutical companies.
Sales per employee for the market as a whole
Assertio (ASRT) is a pharmaceutical company specializing in the commercialization of drugs for neurological diseases. They frequently acquire rights to existing drugs. This metric reflects the effectiveness of their sales team. The increase in revenue per employee indicates that their sales team is successfully maximizing revenue from their drug portfolio.
Short shares by company, segment and market as a whole
Shares shorted by company Assertio Holdings Inc. (ASRT)
Assertio Holdings is a pharmaceutical company whose business model is based on acquiring and commercializing existing, often niche, drugs. This strategy carries risks. This chart shows how many investors are betting that its drugs will face unexpected generic competition or that its acquisition model is unsustainable.
&width=1500&height=450&colorIndex=72&filename=GURU_Markets_-_Short-Shares-Chart-for-the-Company-Assertio-Holdings-Inc.-ASRT&v=1772636772130 "Short Shares Chart for the Company Assertio Holdings Inc. (ASRT)")
Shares shorted by market segment - Neuro
Assertio (ASRT) is a pharmaceutical company specializing in neurology and pain treatments, often acquiring existing, mature products. This chart shows the cumulative short position in the specialty pharmaceutical sector. It reflects market pessimism about their ability to navigate patent cliffs and grow through older drugs.
Shares shorted by the overall market
Assertio (ASRT) is a pharmaceutical company. Unlike R&D biotechs, it has sales, but it also has debt. When this fear indicator rises, investors begin obsessively scrutinizing balance sheets. They sell highly leveraged companies, fearing that ASRT won't be able to service its debt in a recession.
RSI 14 indicator for a company, segment, and market as a whole
The company's RSI 14 indicator Assertio Holdings Inc. (ASRT)
Assertio (ASRT) isn't an R&D company, but a "commercializer." They acquire rights to niche drugs (often for pain) and try to maximize their sales. This chart measures how much confidence investors have in their portfolio. It shows when the stock is "overbought" on expectations or "oversold" on fears of a "patent cliff."
&width=1500&height=450&colorIndex=75&filename=GURU_Markets_-_RSI-14-indicator-chart-for-the-companys-stock-Assertio-Holdings-Inc.-ASRT&v=1772636772167 "RSI 14 indicator chart for the company's stock Assertio Holdings Inc. (ASRT)")
RSI 14 Market Segment - Neuro
Assertio (ASRT) is a "specialty" pharma. They don't *do* R&D, but *commercialize* (sell) *niche* brand-name drugs (e.g., for *migraines*). The "Neuro" (biotech) sector thrives on news. RSI_14_Seg shows the "temperature" of this *entire* segment. It's vital to understand: is ASRT's growth a "niche" or is *the entire* biotech "overheated"?
RSI 14 for the overall market
Assertio (ASRT), a pharmaceutical company, sees this chart as a reflection of the "defensive" nature of its business. Demand for its products (drugs) isn't driven by euphoria or panic—it's driven by patients. During times of market panic, investors often seek safe havens in companies with non-cyclical demand.
Analyst consensus forecast for the company's share price, the segment, and the market as a whole
Analyst consensus stock price forecast ASRT (Assertio Holdings Inc.)
Assertio Holdings is a pharmaceutical company specializing in the commercialization of branded drugs for the treatment of neurological diseases and pain. This chart shows the average target price forecast by analysts, based on its mature product portfolio and patent expiration risks.
&width=1500&height=450&colorIndex=78&filename=GURU_Markets_-_A-chart-showing-analyst-consensus-forecasts-for-the-expected-stock-price.-ASRT-Assertio-Holdings-Inc.&v=1772636772224 "A chart showing analyst consensus forecasts for the expected stock price. ASRT (Assertio Holdings Inc.)")
The difference between the consensus estimate and the actual stock price ASRT (Assertio Holdings Inc.)
Assertio is a pharmaceutical company specializing in the commercialization of existing niche drugs, primarily for the treatment of neurological diseases. This chart clearly demonstrates the upside and downside potential analysts see in the stock. It measures the gap between the price and forecast, reflecting their view of their product portfolio.
&width=1500&height=450&colorIndex=79&filename=GURU_Markets_-_A-chart-showing-the-difference-between-the-consensus-forecast-and-the-actual-stock-price.-ASRT-Assertio-Holdings-Inc.&v=1772636772250 "A chart showing the difference between the consensus forecast and the actual stock price. ASRT (Assertio Holdings Inc.)")
Analyst consensus forecast for stock prices by market segment - Neuro
Assertio (ASRT) is a pharmaceutical company that commercializes approved niche drugs, primarily in neurology and pain management, rather than developing them. This chart shows analysts' overall expectations for the neurology sector. It reflects whether experts believe the drug buy-and-sell model is profitable.
Analysts' consensus forecast for the overall market share price
Assertio Holdings is a specialty pharmaceutical company that acquires and commercializes niche drugs, primarily for the treatment of neurological diseases and pain. This chart shows overall market sentiment. For Assertio, whose business is focused on smart sales rather than risky R&D, overall optimism is important, but their growth depends more on the successful marketing of niche products.
AKIMA index of the company, segment and market as a whole
AKiMA Company Index Assertio Holdings Inc.
Assertio (ASRT) is a portfolio company. They don't develop drugs, but rather acquire mature, niche branded drugs (primarily in neurology and pain management) that are off-patent but still have a sales tail. This chart is an indicator of their cash flow, measuring their ability to squeeze profits out of these older drugs before sales decline to zero.
AKIMA Market Segment Index - Neuro
Assertio Holdings is a pharmaceutical company that acquires and commercializes approved drugs, primarily in neuroscience and pain management. This chart shows the average index for the neuroscience segment. It provides investors with a benchmark for how Assertio's business model (commercialization, not R&D) compares to the sector average.
The AKIM Index for the overall market
Assertio is a pharmaceutical company specializing in neuroscience and pain management. It grows through the acquisition of mature assets. This chart, which reflects the market average, provides a macro backdrop. It helps assess how this consolidation and cash flow generation strategy compares to overall economic trends in the pharmaceutical sector.
